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WHAT THIS PAPER ADDS
 This study demonstrates the high prevalence of hypercoagulable states, especially protein S deﬁciency among patients with
superﬁcial vein thrombosis (SVT) and varicose veins (VVs). The association of thrombophilia with the aetiology and pathogenesis of
the SVT in patients with primary VVs bring new data to the diagnostic approach and treatment of the disease. The need for routine
screening for hypercoagulable states in such patients is debatable. Furthermore, obesity and advanced age are strong independent
factors that predispose to thrombosis.a r t i c l e i n f o
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Objectives: To investigate the association of various risk factors including thrombophilia defects, in
patients with varicose veins (VVs) and history of episodes of superﬁcial vein thrombosis (SVT).
Materials and methods: Two hundred and thirty patients with primary VVs were included in this
prospective study. A total of 128 (43 men, age 56  13) had an acute episode or a previous history of SVT,
while 102 patients (27 men, age 48  12) did not. Coagulation proﬁle investigation included serum levels
of protein C (PC), protein S (PS), anti-thrombin III (AT III), plasminogen (Plg), A2 antiplasmin (A2Apl) and
activated protein C resistance (APCR). This was performed at least 3 months after the SVT episode to
ensure that the results were not altered. Age and body mass index (BMI) were also assessed.
Results: PC deﬁciency was detected in 3/128 (2.3%), PS deﬁciency in 19/128 (14.8%), AT III deﬁciency in
29/128 (22.7%), Plg deﬁciency in 9/128 (7%), A2Apl excess in 3/128 (2.3%) and APCR in 9/128 (7%)
patients with SVT and 0/102 (0%), 3/102 (2.9%), 15/102 (14.7%), 6/102 (5.8%), 0/102 (0%) and 1/102 (0.9%)
in the control group, respectively. BMI greater than 30 kg m2 was associated with SVT. In logistic
regression analysis SVT was associated with PS deﬁciency (odds ratio (OR) 6.7, p ¼ 0.004, 95% conﬁdence
interval (CI) 1.83e24.53), obesity (OR 3.5, p ¼ 0.003, 95% CI 1.53e8.05) and age (OR 1.038, p ¼ 0.001,
95% CI 1.01e1.06).
Conclusions: Obesity, age and PS deﬁciency were found as factors associated with SVT episodes in patients
with VVs.
 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Superﬁcial vein thrombosis (SVT) of the lower limbs is
a common disease reported to affect 3e11% of the generalion 10 e Venous Disease on
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ciety for Vascular Surgery. Publishepopulation.1e3 In patients with varicose veins (VVs) the incidence
of SVT ranged from4e59%withmost common location the varicose
tributaries.3e6 In the past, SVT was considered a benign condition
with good prognosis but recent studies have demonstrated its
potential severity.4
The management of SVT has been changed as a number of risks
factors are associated with the disease.7 Abnormalities of coagu-
lation are associated with saphenous thrombosis but most of the
studies involved patients without VVs.8e10 The overall incidence of
these disorders is low, and screening the general population for
hypercoagulable states is not recommended.d by Elsevier Ltd. All rights reserved.
Table 1
Study population characteristics.
Diseased
group n (%)
Control
group n (%)
p value Odds
ratio
95% CI
No 128 102
Gender (Female %) 85 (73.5%) 75 (66.4%) 0.243
Age (Mean, SD) 48 (12) 56 (13) 0.001
Age >60 y 63 (49%) 26 (25%) <0.001 3.56 1.90e6.68
BMI (Mean, SD) 25 (3.6) 27 (4.7) 0.001
BMI <24.9 kg/m2 44 (34%) 55 (54%)
25 < BMI < 29.9 kg/m2 52 (41%) 35 (34%) 0.038 1.86 1.03e3.32
BMI >30 kg/m2 32 (25%) 12 (12%) 0.002 3.3 1.53e7.22
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SVT, and even less information exists regarding testing of SVT in
patients with VVs. We hypothesised that since all patients with VVs
present blood ﬂow stasis and veinwall abnormalities, an additional
factor needs to be present to explain why some patients develop
SVT and others do not. This prompted us to study the role of
thrombophilia markers, age and body mass index (BMI) in patients
with VVs and SVT.
Materials and Methods
Patients and study design
Patients with an acute or recent episode of SVT referred to our
department between February 2009 and May 2011 were consid-
ered. Patients with previous episodes of deep vein thrombosis
(DVT) or pulmonary embolism (PE), autoimmune disease, malig-
nancy, recent surgery or trauma, prolonged immobilisation, preg-
nancy, sepsis, the use of medications that promotes thrombosis
such as oral contraceptives or hormone replacement therapy and
patients with hepatic or renal insufﬁciency were excluded. Each
patient underwent blood investigation for thrombophilia assess-
ment. Also patients referred to our department during the same
period with VVs without a history of a previous SVT were included
as control group. Demographic data and BMI were recorded, and all
patients had a coagulation proﬁle performed.
All patients underwent duplex ultrasound examination (DUS) of
the superﬁcial and deep veins of the lower limbs. DUS was used to
diagnose SVT, to estimate the extent of the thrombus, to exclude the
presence of DVT and to exclude signs indicative of SVTor DVT in the
control group. A second DUS was performed at the end of the
treatment and prior thrombophilia investigation in all patients to
exclude a residual deep or SVT.
Thus, on the basis of medical history, clinical examination and
DUS, patients were divided in two groups: the ‘diseased group’
with SVT only and VVs, and the ‘control group’ with VVs but
without thrombosis (SVT or DVT).
All patients were informed about the nature and aim of the
research and provided their consent to the participation. The study
was approved by the ethical committee of our institution in
accordance with the Helsinki Declaration.
Body mass index
BMI, a proxy of adiposity, was calculated by dividing weight in
kilograms by the square of the height in metres. According to the
World Health Organization (WHO), patients were categorised in
three subgroups: with normal weight (18.5 < BMI <24.9 kg m2),
overweight (25< BMI<29.9 kg m2) and obese (BMI> 30 kgm2).
Thrombophilia investigation
All patients in the diseased and control group underwent
a thrombophilia proﬁle investigation that included levels of protein
C (PC), protein S (PS), anti-thrombin III (AT III), A2 antiplasmin
(A2Apl), plasminogen (Plg) and activated protein C resistance
(APCR). These are well-established thrombophilia markers predis-
posing to venous thrombo-embolism (VTE).11,12 Thrombophilia
proﬁle was assessed at least 3 months after the SVT episode to
ensure that the results were not affected from anticoagulation
therapy or the acute thrombotic episode. Blood samples were
drawn into four buffered sodium citrate (9:1) vacutainer tubes and
kept on ice until centrifugation at 2500 g for 30 min at 4 C. Deﬁ-
ciency of anticoagulant proteins (PS, PC, AT III and Plg), and high
levels of A2Apl were determined by a chromogenic method whileAPCR was measured using a clotting method based on activated
partial thromboplastin time (aPTT). PS deﬁciency was diagnosed
based on low levels of free PS. APCR carriers underwent a genetic
analysis for mutation G1961A of the factor V gene (FV Leiden).
Statistical analysis
Chi-square tests were applied to initially assess possible statis-
tically signiﬁcant risk factors at p < 0.20. These were then used in
a logistic regression model with the forward likelihood ratio
method. Interactions of all statistically signiﬁcant factors at p< 0.10
were then examined. All factors entered in the ﬁnal model had an
observed signiﬁcance level at <0.05. Statistical analysis was carried
out with the use of SPSS version 18.0.
Results
The study population consisted of 128 patients in the ‘diseased
group’ (43 men, age 56  13) and of 102 patients in the ‘control
group’ (27 men, age 48  12). Nine patients with SVT were not
included as they did not fulﬁl the inclusion criteria.
The great saphenous vein (GSV) was involved in 61 (47%) of the
patients and the small saphenous vein (SSV) only in 1 patient
(0.7%). Among our patients there were ﬁve patients with thrombus
extending close to saphenofemoral junction (SFJ) but not in the
deep veins and in these patients anticoagulation with low-
molecular-weight heparin (LMWH) in therapeutic levels was
given. All patients had reﬂux in the superﬁcial veins as documented
by duplex scanning. Only two patients had isolated reﬂux in the
deep veins (superﬁcial femoral vein).
Table 1 shows the main characteristics of the study population.
Patients in the diseased group were older than controls. Prelimi-
nary statistical analysis with the Pearson Chi-square test showed
that patients older than 60 years had an increased risk of SVT by
3.5-fold compared to younger (odds ratio (OR) 3.56, p < 0.001, 95%
conﬁdence interval (CI): 1.90e6.68). In addition, more patients in
the diseased group were obese and overweight than in the control
group. Compared to those with normal BMI, overweight patients
had an increased risk of developing SVT by 1.8-fold (OR 1.86,
p¼ 0.038, 95% CI: 1.03e3.32) while obese with BMI > 30 kg m2 by
3.3-fold (OR 3.33, p ¼ 0.002, 95% CI: 1.53e7.22).
The results of the thrombophilia markers in two groups after
logistic regression analysis are presented in Table 2. In the diseased
group, 55 patients (43%) had hypercoagulable disorders. Eighty-
nine percent (8/9) of the patients with SVT and 100% (1/1) of the
control group with APCR, respectively, had FV Leiden mutation.
An active ulcer was present in 5/128 among those with SVT and in
2/102 among controls. The presence of at least one thrombophilia
factor was detected in 2/5 and 0/2, respectively. Thirty four (40%) of
the female patients and 49% of the male patients with SVT had
abnormal thrombophilia proﬁle; 14 of the patients had multiple
abnormalities but the number of themwas too small to be analysed
separately.
Table 2
Prevalence of thrombophilia markers.
Diseased
group n (%)
Control
group n (%)
p value
Protein C deﬁciency 3 (2.3%) 0 (0%) 0.220
Protein S deﬁciency 19 (14.8%) 3 (2.9%) 0.004
Anti-thrombin deﬁciency 29 (22.7%) 15 (14.7%) 0.187
Plasminogen 9 (7%) 6 (5.8%) 0.147
A2 Antiplasmin 3 (2.3%) 0 (0%) 0.085
Activate protein C resistance 9 (7%) 1 (0.9%) 0.051
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(p ¼ 0.004). The prevalence of the other disorders was not statis-
tically different between the two groups. In logistic regression
analysis in which only signiﬁcant factors were included, the OR of
developing SVT in patients with VVs increased by 3.8% for each year
of ageing (OR 1.038, p¼ 0.001, 95% CI: 1.01e1.06), 3.5-fold for obese
patients (OR 3.5, p ¼ 0.003, 95% CI: 1.53e8.05) and 6.7-fold in
patients with PS deﬁciency (OR 6.7, p ¼ 0.004, 95% CI: 1.83e24.53).Discussion
Thrombophilia is a hypercoagulable state that clinically presents
with arterial or venous thrombosis. It usually occurs in young
people due to acquired or inherited defects in one or several
members of coagulation cascade.13 Genetic risk factors were ﬁrst
described by Egeberg in 1965,14 reporting an anti-thrombin deﬁ-
ciency that caused DVT.15 In the next decades other hypercoagu-
lable defects in patients with venous thrombo-embolism (VTE)
were described.11,15e17 Although several studies have reported SVT
in patients with thrombophilia, it is estimated that SVT among
patients with varicose tributaries is a complication of varicose vein
disease and no screening for hypercoagulable state is required.2,18
Themain objective of our studywas to investigate the prevalence
of most frequent thrombophilia defects in patients with VVs
complicated with SVT without any other known thrombotic risk
factors. Our data showed a signiﬁcant prevalence of PS deﬁciency in
patients with SVT. Furthermore, while all defects related to inherited
thrombophilia (PC, PS, AT III, Plg, A2Apl and APCR) were more
frequent among patients with SVT, only PS deﬁciency reached
statistical signiﬁcance. All these defects aremore frequent inpatients
with SVT but without VVs and are considered as risk factors.2 A high
prevalenceofPSdeﬁciency inpatientswithSVThasbeendescribed in
numerous studies in patients without VVs.9,11,12,19e22
A total of 56% of the diseased group and 24% of the controls were
found to have at least one thrombophilia defect with most frequent
AT III deﬁciency followed by PS. The incidence of AT III was quite
high in both groups without signiﬁcant difference between them.
Further follow-up among these patients is needed to clarify the
importance of this ﬁnding.
Although damaged vein wall and blood stasis are factors pre-
disposing to thrombosis in patients with varicose veins, the
prevalence of hypercoagulable disorders is also important among
these patients. Nearly half of our patients had an additional
hypercoagulable disorder. A genetic thrombophilic defect such as
PS deﬁciency is probably an important factor predisposing for SVT
in patients with VVs. Physicians should be aware about this, espe-
cially when these patients are assigned for VVs surgery during
which they may be at risk for thrombosis, and thromboprophylaxis
should be considered.
The incidence of venous thrombosis rises from 0.001% in
childhood to nearly 1% in aged subjects.23 As described in the
Prospective Observational Superﬁcial Thrombophlebitis (POST)
study the mean age of developing SVT is 60 years and it is generallyaccepted that people younger than 40 years with a venous
thrombotic episode are likely to have a thrombophilia defect.4 In
most of the studies the mean age of the patients presenting with
SVT was lower than in our study, perhaps because we excluded
patients with a previous DVT and/or PE.11,21,22,24 Moreover, in some
cases, SVT may occur withmild or asymptomatic clinical symptoms
and patients may not present for medical attention. Age is an
important factor that increases the risk of developing SVT in
patients with VVs. On the other hand, younger patients present
more often a coagulation defect: more than half of our patients
under 60 years had a hypercoagulable defect and 20% of them had
more than one defect. This is in accordance with the observation
made in the POST study that the older the patient the fewer risk
factors are needed, while in younger patients with a thrombotic
event hypercoagulability is most common.4
Obesity is a risk factor for VTE since it predisposes to venous
stasis and is associated with many haemostatic disorders. Obesity
enhances thrombosis by increasing prothrombotic factors and
impairing ﬁbrinolytic activity.25e27 The association of obesity and
SVT has been described in several studies.4,7,8,28 The overall risk of
developing SVT in our study increases in obese patients compared
to normal ones. The association remained fairly strong after
adjustment for thrombophilia defects and age.
A possible limitation of our study is that we did not consider the
severity of venous disease according to Clinical-Etiology-Anatomy-
Pathophysiology (CEAP) classiﬁcation.29 Patients with different
varicose status were included. The degree of vein wall damage
represents a strong independent factor for thrombosis. We believe
that SVT in patients with VVs is caused by both independent and
interdependent mechanisms including blood stasis and wall
damage and acquired or inherited hypercoagulability state (Vir-
how’s triad). Also, we did not check our patients for insulin resis-
tance, a factor that is associated with a thrombotic predisposition.
Although we recognised obesity as a risk factor of thrombosis in
patients with VVs, the presence of a signiﬁcant number of obese
patients may have inﬂuenced our results. Over half of our patients
were overweight and 25% in the diseased group were morbidly
obese. Obesity is a risk factor for VVs because of the increased leg
venous pressure. Older, fatter patients are not as mobile as slimmer
ﬁtter patients and this has an obvious inﬂuence on their ability to
clear thrombus. Obesity also predisposes to post-thrombotic
syndrome and vein ulcers.30 High levels of thrombophilia are
seen in patients with venous ulcer.31,32
The currentmanagement of SVT is still debatable, evenmore is the
need for routine thrombophilia screening in patients with SVT and
VVs. In our studywe did not examine the effect of different treatment
modalities in patients with VVs and SVT. Moreover, we did not
examine different treatments in patients with SVT and hypercoagu-
lable disorders. Current recommendations for treatment of SVT
include subcutaneous administration of Fondaparinux at a dose of
2.5mgonceaday for45days and inpatientswith thrombusextension
to the SFJ, anticoagulants at therapeutic doses.3,33 In asymptomatic
patientswith a coagulation defect, thromboprophylaxiswith LMWHs
should be considered when exposed in conditions predisposing to
vein thrombosis such as trauma, surgery and immobilisation. In
patients with multiple genetic defects a more aggressive thrombo-
prophylaxis may be required as it is more likely these patients to
develop a thrombo-embolic event.Whenhypercoagulable disorder is
detected, the ﬁrst-degree relatives of the patient should be screened
as up to one half of the members of the family may be affected.34
In conclusion, our study demonstrates a high prevalence of
hypercoagulable states in patients with SVT. Obesity, ageing and PS
deﬁciency were associated with SVT among patients with VVs.
These ﬁndings may have potential important implications in the
management.
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